Innate immune regulations and various siRNA modalities

Area of Science:

• Biotechnology
• Molecular Biology
• Immunology

Background:

• RNA interference (RNAi) therapeutics, particularly small interfering RNA (siRNA), show promise for treating genetic diseases.
• The inherent immunostimulatory properties of siRNA can lead to off-target effects and nuclease degradation, limiting therapeutic applications.
• Modulating siRNA structure is crucial for enhancing pharmacological attributes and ensuring precise gene silencing.

Purpose of the Study:

• To review innovative siRNA therapeutics and their role in immune regulation for disease silencing.
• To explore how structural modifications in siRNA impact immunogenicity, nuclease resistance, and gene-silencing efficacy.
• To discuss the mechanisms of siRNA-mediated gene silencing and innate immune response induction.

Main Methods:

• Review of existing literature on siRNA modification chemistries and their effects.
• Analysis of various modification designs (STC, ESC, ESC+, disubstrate) for gene silencing.
• Examination of siRNA processing through RISC and induction of innate immune signaling pathways (TLR-dependent and independent).

Main Results:

• Phosphonate modifications shield against phosphorylation, while ribose sugar alterations reduce immunogenicity and improve binding.
• Substitution of bases with virtual/pseudo bases minimizes off-target effects and modulates nucleic acid sensors.
• Various modification strategies effectively silence gene expression for diseases like hepatitis, HIV, and acute kidney injury.

Conclusions:

• siRNA therapeutics can be optimized through structural modifications to enhance efficacy and safety.
• These modifications help control innate immune responses, making siRNA a viable therapeutic strategy.
• Innovative siRNA designs offer a promising approach to managing gene-linked diseases by modulating immune responses.